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Human papillomaviruses (HPVs) are the causative agents of benign and malignant lesions of the epithelium.
Despite their high prevalence, there is currently no antiviral drug for the treatment of HPV-induced lesions.
The ATPase and helicase activities of the highly conserved E1 protein of HPV are essential for viral DNA
replication and pathogenesis and hence are considered valid antiviral targets. We recently described novel
biphenylsulfonacetic acid inhibitors of the ATPase activity of E1 from HPV type 6 (HPV6). Based on kinetics
and mutagenesis studies, we now report that these compounds act by an allosteric mechanism. They are
hyperbolic competitive inhibitors of the ATPase activity of HPV6 E1 and also inhibit its helicase activity.
Compounds in this series can also inhibit the ATPase activity of the closely related enzyme from HPV11;
however, the most potent inhibitors of HPV6 E1 are significantly less active against the type 11 protein. We
identified a single critical residue in HPV6 E1, Tyr-486, substituted by a cysteine in HPV11, which is primarily
responsible for this difference in inhibitor potency. Interestingly, HPV18 E1, which also has a tyrosine at this
position, could be inhibited by biphenylsulfonacetic acid derivatives, thereby raising the possibility that this
class of inhibitors could be optimized as antiviral agents against multiple HPV types. These studies implicate
Tyr-486 as a key residue for inhibitor binding and define an allosteric pocket on HPV E1 that can be exploited
for future drug discovery efforts.
Papillomaviruses infect the squamous and mucosal epithelia
of many different mammals, including humans, often resulting
in the development of benign and sometimes malignant lesions
(reviewed in references 16, 31, and 42). There are over 100
types of human papillomavirus (HPV), each exhibiting a par-
ticular tropism for specific tissue types (8). For example, HPV1
causes plantar warts, HPV6 and -11 cause anogenital warts
(condyloma acuminata), and infection with HPV16 and -18,
among others, can lead to cervical cancer (2, 42). Among the
HPV types that infect the anogenital region, those that are
associated with cancer are collectively referred to as “high-
risk” types, whereas those that cause only benign warts are
known as “low-risk” types (42). Despite the medical burden
associated with treating and screening for HPV infections, an
HPV-specific antiviral drug is still lacking, and there are only a
few reports of HPV-specific inhibitors which could serve as
potential leads for drug discovery. To our knowledge, the E1
ATPase inhibitors described in this report and our previously
published series of E2 inhibitors (37, 39) are the only potent
and selective small molecules targeting HPV DNA replication
proteins ever to be reported.
All papillomaviruses have a small circular double-stranded
DNA genome which encodes for only eight well-characterized
proteins (for a recent review, see reference 21). The most
highly conserved protein, and the only one with enzymatic
activity, is the E1 helicase (reviewed in references 33 and 40).
E1 is an attractive target for the development of anti-HPV
drugs because it is essential for viral replication and pathogen-
esis (24, 34). Indeed, it has been shown in the cottontail rabbit
papillomavirus (CRPV) infection model that frameshift muta-
tions in the E1 open reading frame abrogate the ability of the
CRPV genome to induce papillomas when inoculated into the
skin of domestic rabbits (41).
E1 is the replicative helicase of papillomaviruses. It binds
cooperatively to the origin of replication in conjunction with
the E2 protein (12, 22, 27, 30). Formation of the E1-E2-origin
complex involves not only the binding of both proteins to
specific DNA elements in the origin but also a protein-protein
interaction between the N-terminal transactivation domain of
E2 and the helicase/ATPase domain of E1 (1, 3, 4, 36). We
recently reported a class of small-molecule inhibitors of HPV
DNA replication that bind to the transactivation domain of E2
and prevent its interaction with E1 (37, 39). Assembly of the
E1-E2-ori complex facilitates the recruitment of additional E1
molecules to the origin, which assemble into hexamers in a
reaction that is stimulated by ATP binding (11, 26, 35). These
hexamers are the catalytically active form of E1 capable of
melting the origin and unwinding the viral DNA ahead of the
replication fork (28). As is the case for most helicases, the
DNA-unwinding activity of E1 is powered by the hydrolysis of
ATP. We previously characterized the enzymatic activities of
highly purified recombinant HPV6 and -11 E1 proteins, pro-
duced with a baculovirus expression system (38). These studies
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revealed that HPV6 and -11 E1 proteins have similar Km values
for ATP (12 and 6 M, respectively) and that the ATPase and
unwinding activities are contained within the C-terminal half
of E1 (amino acids 353 to 649), the same region that binds to
E2 (38). Interestingly, we found that E2 hinders the ATPase
activity of E1 by raising its Km for ATP approximately seven-
fold. Conversely, we observed that ATP impairs the coopera-
tive binding of E1 and E2 to the origin, most likely by weak-
ening the E1-E2 protein-protein interaction (38). These results
and others led to the proposal that ATP not only powers the
helicase activity of E1 but also acts as a molecular trigger
during the initiation of viral DNA replication to help sever the
interaction of E1 with E2 and promote its hexamerization at
the origin (26, 38).
We recently reported on the discovery, by high-throughput
screening of our compound collection, of a biphenylsulfon-
acetic acid inhibitor of HPV6 E1 (compound 1; Table 1) (10).
This compound inhibits the ATPase activity of HPV6 E1 with
a 50% inhibitory concentration (IC50) of 3 M at an ATP
concentration of 1 M. More potent derivatives of this original
TABLE 1. Inhibitor potency against HPV6, 11, and 18 E1 ATPasesa
Inhibitor
no.
Structure of: IC50 (nM)
R1 R2 HPV6 HPV11 HPV18
1 2,000  400 14,000  2,000 3,600  1,300
2 160  40 3,300  1,000 620  70
3 190  40 3,200  300
4 170  30 3,000  600
5 2,000  700 1,800  10 6,900  1,900
6 20  3 11,000  6,000
7 32  4 12,000  2,000 11,000  20
8 4.5  0.6 11,000  7,000
9 4.3  1.1 3,400  1,700 2,300  40
a HPV6 and 11 E1 ATPase assays were carried out with purified full-length E1 proteins and 1 M ATP. Values are averages of at least duplicate and in most cases
four or more experiments. HPV18 E1 ATPase assays were carried out with in vitro-translated helicase domain (amino acids 357 to 659) and 1 M ATP (see Materials
and Methods). Values are averages of duplicate experiments.
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hit were identified which inhibited activity with IC50 values as
low as 4 nM. Here we show that these more potent inhibitors
of HPV6 E1 are less active against the related HPV11 E1
protein and that a single amino acid difference between the
two enzymes accounts for most of this differential inhibition.
Furthermore, we describe the kinetic mechanism of action for
these compounds and the activity of more potent compounds
against the helicase activity of E1. Together, these results de-
fine a pocket in E1 that can be exploited for small-molecule
modulation of E1 activity.
MATERIALS AND METHODS
Proteins and inhibitors. HPV6a and HPV11 E1 proteins were expressed in
insect cells using a baculovirus system and purified by nickel affinity chromatog-
raphy as described previously (38). E1 helicase domains were synthesized in vitro
by coupled transcription/translation using the TNT reticulocyte lysate system
(Promega). Plasmids encoding the helicase domains of HPV16, HPV18, and
CRPV E1 were constructed by PCR amplification from viral genomic DNA
obtained from ATCC, followed by ligation into plasmid pTM1. pTM1 contains
the encephalomyocarditis virus internal ribosome entry site region downstream
of the bacteriophage T7 promoter (23). A sequence encoding a C-terminal
FLAG epitope (Met Asp Tyr Lys Asp Asp Asp Asp Lys; Kodak) was added
during the PCR. Plasmids encoding HPV6-11 chimeras were constructed by
PCR-mediated ligation as described previously (6) and cloned into pTM1. Site-
directed mutagenesis was performed using the QuikChange kit (Stratagene)
according to instructions supplied by the manufacturer. Additional details on the
construction of these plasmids are available on request. Most inhibitors used in
this study have been reported previously (10). Compounds 3, 4, and 5 were
synthesized using similar procedures.
E1 ATPase assays in solution. Most solution assays were performed using the
previously reported scintillation proximity method (19). Briefly, 45-l reactions
were carried out in assay buffer (20 mM HEPES, pH 7.5, 1 mM dithiothreitol,
0.05 mM EDTA, 0.005% IGEPAL-CA630 [vol/vol]; Sigma [equivalent to Non-
idet P-40]) supplemented with 2% dimethyl sulfoxide. Reaction mixtures con-
tained 1 M ATP, unless stated otherwise, and a concentration of Mg(OAc)2 500
M greater than that of ATP. [-33P]ATP was included either at 30 nCi/well in
reactions performed at 1 M of total ATP or at 100 Ci per mol of unlabeled
ATP in initial velocity studies. Detection was performed by adding to reaction
mixtures 40 l of a suspension of scintillation proximity beads (10 mg/ml; Am-
ersham Biosciences) in ammonium molybdate (0.67%) and 0.8 M HCl, followed
by a solution of 100 mM citric acid and 7 M cesium chloride (80 l). Scintillation
signals were quantified using a TopCount NXT microplate scintillation counter
(Packard Instruments). To verify inhibitor specificity, reactions were carried out
with either purified herpes simplex virus helicase primase (2 nM) (9) or SV40 T
antigen (30 nM) (32) under the same conditions used for E1. Approximately
20% conversion of the ATP substrate was obtained at these concentrations of
enzymes and under these reaction conditions.
Kinetic parameters were determined by initial velocity experiments. Reactions
were performed in total volumes of 160 l rather than 45 l. Twenty-microliter
samples were removed at multiple time points and quenched with 40 l of
ammonium molybdate-scintillation proximity bead suspension followed by 80 l
of citric acid-cesium chloride. The concentration of product formed at each time
point was estimated by determining, for each experiment, a conversion factor
relating nM of phosphate product (determined from the ratio of ATP to ADP
measured by thin-layer chromatography) to cpm detected by scintillation prox-
imity. Because of the multiple steps involved in this procedure and the relatively
high variability in quantification by thin-layer chromatography, estimates of the
absolute concentrations of phosphate were found to vary by a factor of 2,
although the relative concentrations obtained for different time points or reac-
tion wells were determined much more accurately. This procedure has been
described in detail previously (19). Kinetic data were analyzed using the equa-
tions for linear or hyperbolic competitive inhibition (29) with the program GraFit
3.0 (Erithacus Software Ltd.).
E1 helicase assays. Helicase assays were carried out using the same buffer used
for ATPase assays and the method described previously (38). Briefly, reaction
mixtures contained HPV6 E1 (10 nM), a partial duplex substrate consisting of a
33P-labeled 24-base oligonucleotide covalently linked to biotin and annealed to
M13 single-stranded DNA, ATP at 300 M unless stated otherwise, and
Mg(OAc)2 at a concentration 500 M greater than the ATP concentration.
Reaction mixtures were incubated at 37°C for 30 min, and products were de-
tected by addition of streptavidin-coated scintillation proximity beads.
In the experiment used to measure inhibition by ATP--S, helicase assays were
carried out essentially as described above, except that ATP and Mg(OAc)2
concentrations were 300 M and 1 mM, respectively. Helicase and ATPase
activities were detected by removing two 20-l aliquots from 60-l reaction
mixtures. One aliquot was used to quantify helicase activity by measuring the
amount of unwound oligonucleotide product following separation from the sub-
strate by electrophoresis on 20% acrylamide gels, as described previously (38).
The other aliquot was used to quantify ATP hydrolysis by a colorimetric method
using ammonium molybdate and malachite green (18).
ATPase assays using immobilized E1. We previously showed that the helicase
domain of HPV11 E1 (amino acids 353 to 649) made by in vitro transcription/
translation is oligomeric (35) and has ATPase activity comparable to that of the
full-length protein (38). HPV6 and -11 E1(353–649) were immobilized on plates
through an affinity-purified rabbit antiserum directed against the C-terminal 14
amino acids of HPV11 E1. The purified antibody (1 g/well) was immobilized in
white Maxi-Sorp 96-well plates (Nunc) by incubation for 1 h at room tempera-
ture (or overnight at 4°C) in 100 l antibody coating buffer (100 mM potassium
phosphate, pH 6.5, 0.02% sodium azide, 0.001% glutaraldehyde). After removal
of the coating solution, the plates were blocked for 1 h at room temperature (or
4°C overnight) with 200 l/well of antibody blocking buffer (50 mM phosphate-
buffered saline, 1% sucrose, 0.05% casein, 0.05% sodium azide). Blocking buffer
was removed by aspiration, and coated plates were stored at 4°C until needed, up
to 3 months. For reactions with FLAG-tagged E1 proteins, the monoclonal
antibody M2 (Kodak) was immobilized by the same procedure. On the day of the
experiment, plates were washed once with 200 l of E1 coating buffer (20 mM
Tris, pH 7.6, 500 mM NaCl, 0.02% NP-40 [vol/vol], 5 mg/ml bovine serum
albumin, 1 mM dithiothreitol). In vitro-translated helicase domains (2 l/well of
the translation reaction for the HPV6 and -11 proteins or 8 l/well for the
others) were immobilized by incubation for 1 h at room temperature in E1
coating buffer (100-l total volume). Negative control wells contained 2 l or 8
l per well of an in vitro translation reaction mixture programmed with pTM1
plasmid. Wells were then washed three to five times in wash buffer (same as
ATPase buffer described above but supplemented with 100 mM NaCl and 0.1%
[vol/vol] Triton X-100). Thorough washing was needed to remove proteins from
the in vitro translation mixture, other than E1, that have ATPase activity. Effi-
cient removal of these contaminating ATPases was verified by comparing the
signals in negative control wells to those in wells in which no in vitro translation
mixture was added. To determine the activity of the immobilized E1, 45-l
ATPase reactions were carried out and products were detected exactly as in the
solution-reaction protocol. The activities of the HPV6 and HPV11 proteins, and
of the chimeras and mutants derivatives thereof, varied by a factor of 3, but we
did not determine whether this variation was caused by differences in catalytic
efficiency of the enzymes or differences in the level of protein obtained by in vitro
translation. Activity for the HPV16, HPV18, and CRPV enzymes was lower. In
control experiments, we determined that immobilization of purified HPV6 and
HPV11 E1 did not affect their activities or their levels of inhibition by the
ATPase inhibitors (data not shown).
RESULTS
Mechanism of action of E1 ATPase inhibitors. We previ-
ously reported on the identification of a class of specific, small-
molecule inhibitors of the ATPase activity of HPV6 E1 (10).
The properties of representative members of this class are
indicated in Table 1. Unless stated otherwise, the ATPase
assays used in this study were performed at 1 M ATP, a
concentration well below Km (12 M), and using a recently
described scintillation proximity method (19). Under these
conditions, the original lead inhibitor, compound 1, had an
IC50 of 2 M for HPV6 E1 and a slightly higher IC50 of 14 M
for inhibition of the closely related HPV11 E1. At 80 M, it
had no effect on the ATPase activity of either HSV helicase
primase or the more closely related SV40 T antigen, highlight-
ing its specificity towards E1. Compound 1 served as a lead for
a medicinal chemistry investigation (10), and IC50 values for
related inhibitors are given in Table 1. As reported previously
(10), significantly improved affinity for HPV6 E1 was obtained
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through the addition of substituted amides at the 3 and 4
positions of the biphenyl moiety. However, these substitutions
provided at best modest improvements in affinity for the
closely related HPV11 E1.
Preliminary experiments indicated that inhibitor 1 and other
compounds in this series were less active at higher ATP con-
centrations, suggesting that they might be competitive inhibi-
tors. Data from initial velocity kinetic experiments using a
range of ATP and inhibitor concentrations were collected and
analyzed by nonlinear regression as well as by visual examina-
tion of Lineweaver-Burke double-reciprocal plots. Systematic
deviations of the residuals were observed after fitting to a
linear competitive mechanism (Fig. 1A, dotted lines). One
hallmark of the standard linear competitive mechanism is that
a replot of the slopes for each inhibitor concentration from the
Lineweaver-Burke plot should yield a straight line versus in-
hibitor concentration. This was not observed for compound 7
and other inhibitors in this series. Rather, a replot of their
slopes yielded a hyperbolic curve (Fig. 1B), which is the defin-
ing characteristic of hyperbolic inhibition. As expected, a much
better fit was observed for the hyperbolic competitive mecha-
nism (Fig. 1A, solid lines), which allows formation of both the
binary enzyme-inhibitor and ternary enzyme-inhibitor-sub-
strate complexes but assumes that both complexes turn over
substrate at the same rate (Fig. 1C) (29). Fitting to a more
complex mechanism, in which the substrate turnover of these
two complexes is different (hyperbolic noncompetitive inhibi-
tion (29), did not improve the fit. Values for the parameter ,
the degree to which saturation with inhibitor raises the appar-
ent value of Km for substrate or conversely the degree to which
saturation by substrate raises the apparent Ki of the inhibitor,
ranged from 10 to greater than 100 for different inhibitors in
this series (Table 2). One consequence of this mechanism is
FIG. 1. Kinetic mechanism of compound 7. (A) Lineweaver-Burke
double reciprocal plots for initial velocity data using 10 nM HPV6 E1
and 12.5 to 100 M ATP. Data points correspond to observed initial
velocities for inhibitor concentrations of 480 nM (black triangles), 240
nM (red squares), 120 nM (green circles), 60 nM (blue squares), 30 nM
(brown asterisks), and 15 nM (black circles), as well as those observed
(obs) without inhibitor (magenta diamonds). Corresponding lines were
determined by nonlinear regression using the full data set to the
equations for linear competitive or hyperbolic competitive inhibition
(dotted or solid lines, respectively). The kinetic parameters obtained
for compound 7 from the hyperbolic competitive fit are given in Table
2 (first of the two experiments). (B) Slope replot. For each inhibitor
concentration in panel A, the slope of the 1/v versus 1/[S] plot was
determined by linear regression, and these slopes are plotted versus
inhibitor concentration (diamonds). Lines are plotted for the predicted
slopes after fitting to the linear or hyperbolic competitive mechanisms
(dotted or solid lines in both panels A and B). The solid line corre-
sponds closely to the experimentally determined slopes. (C) Scheme
for the hyperbolic competitive mechanism (29). The parameter  in-
dicates the degree to which inhibitor binding affects substrate binding,
or vice versa. Values of  greater than 1 indicate that binding of one
ligand weakens binding of the other. As  approaches infinity, the
lower line becomes insignificant and the mechanism becomes indistin-
guishable from linear competitive inhibition. For a relatively slow
enzyme such as E1, it is expected but not rigorously proven that the
value of Km is approximately equal to the substrate dissociation con-
stant Ks and the value of kcat is approximately equal to the rate con-
stant for conversion of bound substrate to product, kp.
TABLE 2. Kinetic parameters for inhibition
of HPV6 E1 ATPase activity a
Inhibitor
no.
kcat
(min1)
Km
(M)
Ki
(nM) 
4 (1) 3.5  0.1 12  1 190  20 70  30
4 (2) 6.0  0.1 16  1 130  8 220  120
6 (1) 3.0  0.1 11  1 26  5 11  2
6 (2) 6.3  0.2 15  2 17  2 15  2
7 (1) 4.6  0.1 16  1 35  5 10  1
7 (2) 3.9  0.1 17  1 59  8 13  2
a Kinetic parameters were determined from ATPase assays using 10 nM pu-
rified recombinant HPV6 E1, ATP concentrations of 12.5, 25, 50, and 100 M,
and twofold serial dilutions of inhibitors ranging from 100 to 3,200 nM (inhibitor
4), or 15 to 480 nM (inhibitors 6 and 7). Initial rates were determined from
multiple time points corresponding to 20% conversion and fit to the hyperbolic
competitive inhibition model using GraFit 3.0 (Erithacus Software). For each
compound, fitted values obtained from two independent runs are presented
separately, together with standard errors from the fit. The experiment-to-exper-
iment variability in kcat values is due primarily to the indirect method used to
quantify the absolute concentration of product formed (see Materials and
Methods).
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that at high concentrations of substrate (i.e., near or above
Km), the enzyme is active even at saturating inhibitor con-
centrations. In practice, inhibitors giving high values of  may
appear to act by the simpler linear competitive mechanism. An
important conclusion from these results is that compounds in
this series do not bind directly at the ATP-binding site, but
rather affect substrate binding through an allosteric mecha-
nism. Other examples of this kinetic mechanism have been
reported for both synthetic and natural allosteric inhibitors
(see Discussion).
Consistent with ATP hydrolysis being required for helicase
activity, the biphenylsulfonacetic acid inhibitors did inhibit the
ability of HPV6 E1 to unwind a partial-duplex DNA substrate
comprised of a 24-base-long oligonucleotide annealed to M13
DNA (Table 3 and Fig. 2). The degree of inhibition was de-
pendent on the concentration of ATP used in the assay, as
anticipated from the mechanism of action of these inhibitors.
The potency of the inhibitors in helicase assays could not be
assessed at ATP concentrations as low as those used in ATPase
assays because, as we reported previously, ATP concentrations
much greater than 1 M (typically 300 M) are needed to
observe robust unwinding activity in vitro (38). The higher
ATP concentrations used in unwinding assays is certainly a
major factor underlying the increased IC50 values of the inhib-
itors in these assays relative to those measured in ATPase
assays. However, it is not the only factor since the potency of
these inhibitors, as well as that of the ATP analog ATP--S,
was 3- to 15-fold lower than that predicted solely on the basis
of the higher ATP concentration. For example, we obtained an
IC50 for compound 8 of 1.4 M in a helicase assay performed
at 100 M ATP (Table 3) but a lower value of 100 nM for
inhibition of ATPase activity at the same ATP concentration.
Hence, other factors related to differences in assay kinetics
and/or conditions (e.g., temperature or the presence of nucleic
acids) probably also influence inhibitor potency. Further ex-
periments will be required to pinpoint these additional con-
tributing factors. Nevertheless, it remains that the main con-
clusion from the above results is that the biphenylsulfonacetic
acid class of inhibitors is capable of abrogating the helicase
activity of E1. We also tested whether these inhibitors could
affect other activities of E1 that are modulated by ATP, spe-
cifically its ability to oligomerize into hexamers and its coop-
erative binding with E2 to the origin (see introduction). In
neither case, however, did we observe any significant inhibition
(data not shown), perhaps because high ATP concentrations
are needed in both of these assays.
Identification of an amino acid responsible for the lower
potency of biphenylsulfonacetic acid inhibitors against HPV11
E1. The difference in sensitivity to inhibition we observed be-
tween the HPV6 and -11 proteins was initially surprising be-
cause the helicase domains (residues 353 to 649) (38) of these
two proteins differ by only 21 amino acids. Furthermore, we verified
that these inhibitors act against HPV11 E1 with the same
hyperbolic competitive mechanism as observed for the HVP6
enzyme (data not shown). Altogether, this information sug-
gested that differences in a very limited number of residues
account for most of the observed difference in inhibitor affinity.
We sought to identify these residues by a series of mutagenesis
experiments.
To facilitate these studies, we adapted our standard scintil-
lation proximity method to measure the ATPase activity of the
isolated helicase domain of E1 (amino acids 353 to 649), made
by in vitro translation in a reticulocyte lysate. We found that
the ATPase activity of the helicase domains of HPV6 and -11
E1 proteins could be measured following immobilization of the
proteins in 96-well plates with an antibody specific for the C
terminus of the protein and removal, by several washes, of the
contaminating ATPase activities present in the reticulocyte lysate.
This methodology was used to quickly narrow down a region
in the helicase domain of HPV11 E1 responsible for its lower
sensitivity to the biphenylsulfonacetic acid inhibitors. Specifi-
cally, genes encoding the four HPV6-HPV11 E1 chimeric pro-
teins shown in Fig. 3A were constructed, and the correspond-
ing in vitro-translated proteins were tested for inhibition by
compound 3 (Fig. 3B). Whereas relatively weak inhibition was
observed for the HPV11 protein and for chimera A, this com-
pound inhibited the activity of chimeras B, C, and D to a
similar extent as that of the HPV6 helicase domain. Similar
results were obtained with other inhibitors of the same class
(data not shown). These results indicated that the region of E1
between amino acids 438 and 493 plays a substantial role in
inhibitor sensitivity. Within this region, only three residues, at
positions 461, 486, and 493, are not conserved between HPV6
and HPV11 E1. To test if one or more of these residues were
FIG. 2. Inhibition of HPV6 E1 helicase activity. Effect of com-
pounds 2 (closed circles) and 8 (open circles) on HPV6 E1 helicase
activity. An ATP concentration of 100 M and serial 2.5-fold dilutions
of the inhibitors (160 to 0.7 M) were used. Data points are averages
of duplicate values and are connected by lines to aid in visualization.
The IC50 values obtained from these curves are given in Table 3.
TABLE 3. Inhibitor potency against HPV6 E1 helicase activity a
Inhibitor
no.
IC50 (M) for ATP concn of:
300 M 100 M 30 M
2 26 6.6 3.6
8 3.2 1.4 0.45
a Helicase assays were performed at 37°C as described in Materials and Meth-
ods, using 42 nM purified HPV6 E1, 0.05 nM radiolabeled partial duplex sub-
strate, the indicated concentration of ATP, and Mg(OAc)2 at 800 M, 600 M,
or 530 M (500 M excess over the ATP concentration). IC50 values were
derived using averages of duplicate data points. The curves for 100 M ATP are
shown in Fig. 2.
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responsible for the observed potency differences, they were
individually mutated in the context of the isolated helicase
domain of HPV11 E1 to the corresponding residue in HPV6
E1. The substitution of Cys-486 for Tyr substantially increased
the sensitivity of HPV11 E1 to inhibition by the more potent
inhibitor, 9 (Fig. 3C), as well as by other biphenylsulfonacetic
acids with various substituents at C-3 or C-4 (data not
shown). The IC50 value determined for HPV11 E1 C486Y was
24 nM, only fourfold higher than that measured for the HPV6
protein (5.6 nM). Note also that the IC50 of compound 9
against the helicase domain of HPV6 E1 made in vitro is very
similar to the value of 4.3 nM obtained with purified full-length
HPV6 E1 (Table 1), further supporting the notion that the
N-terminal domain of E1 plays no significant role in ATP
hydrolysis. From these results, we conclude that a tyrosine at
position 486 of the E1 helicase domain is important for inhib-
itor binding.
Activity of biphenylsulfonacetic acid inhibitors against E1
from other papillomavirus types. The method described above
using in vitro-translated E1 helicase domains for ATPase as-
says also provided a facile procedure for testing the activity of
this series of inhibitors against the E1 proteins of various
papillomavirus types. Constructs for the E1 helicase domains
of high-risk types 16(352–648) and 18(357–659) as well as that
from the CRPV E1(306–649) were used for in vitro translation
(see Materials and Methods). Due to significant variation in
the C-terminal sequences, the antibody raised against HPV11
E1 did not bind to these proteins (data not shown). Thus, we
made constructs which appended the FLAG epitope to the C
terminus to facilitate immobilization with an anti-FLAG anti-
body. For comparison, a similar C-terminal FLAG-tagged
HPV11 E1 helicase domain was constructed and found to give
activity similar to that obtained using the untagged protein im-
munoprecipitated with the anti-E1 antibody (data not shown).
ATPase activity observed with the high-risk E1 or CRPV
protein was lower than that observed for HPV11 and -6, and
significant activity could only be observed using larger amounts
of protein (data not shown). The enzymatic properties of E1
from these other HPV types have not been well characterized
in the literature, and further experiments will be required to
determine whether this lower activity was due to lower protein
FIG. 3. Amino acid 486 of HPV6 and HPV11 E1 is a key determi-
nant of inhibitor potency. (A, top) Schematic representation of the E1
helicase domain, with the four regions (labeled A to D) (5) of simi-
larity to SV40 T antigen indicated by black boxes. Arrows indicate the
positions of the highly conserved Walker A and B motifs, involved in
ATP binding and hydrolysis. Positions of residues differing in the
HPV6 and -11 sequences are indicated by black bars. (Bottom) Sche-
matic representations of chimeras A to D, with portions derived from
HPV11 in black and those derived from HPV6 in white. Chimeras A
to D have residues corresponding to HPV6 up to amino acids 437, 493,
531, and 582, respectively. Amino acids 461, 486, and 493, the three
amino acid differences between chimeras A and B, are indicated by
asterisks. (B) Inhibition observed in ATPase assays using 2 M com-
pound 3 for HPV11 and -6 E1 as well as the four chimeras. Values are
averages of duplicate data points with the standard deviations indi-
cated. Reactions without inhibitors gave signals from 2,000 to 6,000
cpm depending on the protein. Signals from blank reactions (360 cpm)
were subtracted to determine percent inhibition. (C) Inhibition ob-
served in ATPase assays using 10 nM of inhibitor 9 for HPV11 and -6
E1 as well as HPV11 mutants L461F, C486L, C486Y, and K493S.
(HPV16 E1 encodes a leucine at position 486 but the same residue as
HPV11 at the other two positions.) Values are averages of duplicate or
quadruplicate data points with the standard deviations indicated. In
this experiment, reactions without inhibitor had 3,000 to 9,000 cpm,
whereas blanks, subtracted before calculating percent inhibition, had
300 cpm. IC50 values obtained for two of the proteins in a separate
experiment are also given.
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expression levels, a lower degree of oligomerization, or differ-
ences in kinetic parameters. Regardless, compound 9 at 80 M
clearly inhibited the HPV18 enzyme, but had only a modest
effect on CRPV E1 and no discernible activity against the
HPV16 enzyme (Fig. 4). Several inhibitors had similar or even
greater activity against HPV18 E1 than we had observed
against the HPV11 protein (Table 1). Interestingly, for both
HPV18 and CRPV, the residue corresponding to Tyr-486 is
also a tyrosine, whereas it is a leucine in HPV16. These obser-
vations are consistent with the need for a tyrosine at position
486 for optimal compound binding (Fig. 3C).
DISCUSSION
Many viral pathogens, including HPV, hepatitis C virus, and
herpes simplex virus, encode helicases which are essential for
viral replication and pathogenesis and which therefore have
been considered attractive drug targets (13). However, despite
screening campaigns by multiple companies, relatively few he-
licase inhibitors have been reported (13). We have shown here
that a series of biphenylsulfonacetic acid compounds, identi-
fied using an assay optimized to discover inhibitors of ATP
hydrolysis, can inhibit the helicase activity of HPV6 E1. Al-
though the activity of these inhibitors was affected by the con-
centration of ATP, kinetic studies revealed that they are hy-
perbolic competitive inhibitors. This mechanism implies that
the biphenylsulfonacetic acid inhibitors must bind in another
location than ATP and thus affect ATP binding through an
allosteric mechanism. Inhibitors acting by such a mechanism
would be effective if they can increase the apparent Km of ATP
in vivo sufficiently to bring about a significant reduction in viral
helicase activity in infected cells. They should be inherently
selective since they do not bind to the highly conserved ATP
pocket. Several examples of inhibitor with this mechanism of
action have been reported in the literature. These include
lavendustin-A, a tight-binding peptidic inhibitor of the epider-
mal growth factor receptor tyrosine kinase (17), and peptide
A-183, an inhibitor of factor VIIa identified from a phage-
display peptide library (7, 25).
The crystal structure of the HPV18 E1 helicase domain has
recently been reported (1), and it is interesting to use this
structure to speculate on the location of the biphenylsulfon-
acetic acid binding site. The residue identified in our studies,
Tyr-486 in HPV6 E1 (corresponding to Tyr-492 in HPV18;
Fig. 5A), is close to the ATP binding site, on the same -helix
as the highly conserved Lys-484 (Lys-490 in HPV18), which
interacts with ATP and is essential for catalysis (15). This
FIG. 5. Structure of HPV18 showing the possible binding region of
biphenylsulfonacetic acid inhibitors. (A) Sequence alignment of part of
the helicase domains of the E1 proteins from two low-risk (HPV6 and
-11) and two high-risk (HPV16, and -18) HPV types as well as those of
bovine papillomavirus 1 (BPV1) and CRPV. Fully conserved residues
are red, highly conserved residues are blue, and others are black. The
positions of Tyr-486 in HPV6a E1 and of the corresponding amino
acids in other E1 proteins are highlighted. For the entire helicase
domain, the two low-risk sequences are 93% identical, whereas the two
high-risk sequences are 65% identical. For other possible pair-wise
combinations, the sequence identity ranges from 50% to 60%. (B) Rib-
bon diagram for the HPV18 E1 helicase domain (1). The Walker A
and B motifs involved in ATP binding are blue and orange, respec-
tively. The side chains of the catalytic Lys-490 and Tyr-492 are shown
extending in opposite directions from the -helix (equivalent to Lys-
484 and Tyr-486, respectively, in HPV6 E1). This illustration was
created using Viewer Lite version 5.0 (Accelrys).
FIG. 4. Determination of ATPase activity and compound inhibi-
tion for HPV16, HPV18, and CRPV E1 proteins. Scintillation prox-
imity ATPase assays were performed using in vitro-translated E1
helicase domains immobilized via the anti-FLAG antibody. Raw
cpm are shown for negative controls (in vitro translation reactions
programmed with empty pTM1 vector alone; white bars), and E1
reactions in the absence of inhibitor (black) or in the presence of
80 M compound 5 (dark gray) or 9 (light gray). Error bars corre-
spond to standard deviations for quadruplicate values. Values for
percent inhibition were calculated by comparing blank-subtracted
reactions in the presence and absence of inhibitor and are given
above the corresponding gray bars.
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crystallized domain of E1 is monomeric, but based on the
structure of hexameric SV40 T antigen (14, 20), which is ho-
mologous to E1, Tyr-486 should be near to but not at the
monomer-monomer interface. Although we have not provided
evidence that the biphenylsulfonacetic acids interact directly
with Tyr-486, this is a likely possibility. The tyrosine side chain
extends from the -helix in the opposite direction as does the
lysine (Fig. 5B). Inhibitors interacting with this tyrosine could
cause a conformational change that would affect binding of
ATP, consistent with the allosteric mechanism observed for
this series. Using the Site Finder application of the MOE soft-
ware package (Chemical Computing Group Inc., Montreal,
Canada), we found no potential small-molecule binding sites on
the surface of HPV18 E1 except for the ATP binding site, so it is
conceivable that these compounds bind through an induced-fit
mechanism.
The importance of Tyr-486 for compound binding provides
some rationalization for the differences in inhibitor affinity
observed for the different HPV types. Both HPV18 and CRPV
E1 have a tyrosine at this position, whereas HPV16 has a
leucine. The HPV18, HPV16, and CRPV helicase domains
share 50 to 60% sequence identity with HPV6 E1, compared to
93% for HPV11. It appears that along with this tyrosine,
enough critical residues are conserved in the HPV18 protein to
maintain some affinity for many compounds in this series, in
contrast to the HPV16 and CRPV proteins. A better under-
standing of the type specificity of these inhibitors and other
aspects of their binding will be possible when a high-resolution
structure of an inhibitor-E1 complex becomes available.
The work presented here has highlighted the presence of a
small-molecule binding pocket on at least some HPV E1 pro-
teins. Guided by structural information, it may now be possible
to develop compounds active against not only HPV6 and -11
E1 but also HPV18 and possibly other high-risk proteins. Al-
though the novel ATPase inhibitors presented in this work
currently lack the necessary physicochemical properties to be
good drug candidates (10), they clearly show the potential for
compounds targeting this site to inhibit E1 ATPase and heli-
case activities and thus potentially to serve as antivirals for HPV.
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